BioSpace News Archive

AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the initiation of a Phase 3 registrational study of posoleucel, an allogeneic, off-the-shelf, multi-virus-specific T-cell (VST) therapy.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that it is expanding its mRNA pipeline with two new development programs.

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), announces the following patent notifications and awards relating to the Company’s three lead drug candidates.

2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021.

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced results from its Phase 2 study of lucinactant (KL4 surfactant) for patients with severe COVID-19 associated acute respiratory distress syndrome (ARDS) and lung injury.

Decibel Therapeutics announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in the following upcoming virtual investor conferences in March.

Scholar Rock today announced that it is presenting encore data in an e-poster at the American Academy of Neurology (AAN) 2022 Annual Meeting, taking place in Seattle, Washington (April 2-7) and virtually (April 24-26).

Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat and one-on-one investor meetings at the Maxim Virtual Growth Conference, to be held March 28-30, 2022.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer.

Kane Biotech Inc. announced positive results from biocompatibility and in vivo safety studies in preparation for human clinical trials set to begin later this year.